Cancer remains one of the leading causes of death in the United States. While advances in treatment have improved survival for many patients, where a person lives, their income, and their access to healthcare still play a major role in whether cancer is found early or late.

A new generation of blood tests known as multicancer early detection (MCED) tests could help change that. These tests are designed to detect signals from multiple cancers through a single blood draw, often before symptoms appear. Researchers and policymakers say the technology has the potential to transform cancer screening, especially for cancers that currently have no routine screening options. Yet experts also warn that the benefits will only be realized if access reaches the communities that have historically been left behind.

A New Tool in the Fight Against Cancer

Unlike traditional screening tests that focus on a single disease, MCED tests analyze biological signals in the blood that may indicate the presence of several different cancers at once. Scientists have been studying these tests as a way to complement existing screenings for breast, cervical, colorectal, lung, and prostate cancers. They may also help identify cancers that are often diagnosed only after symptoms develop, when treatment is more difficult and survival rates are lower.

The need for better early detection is significant. According to researchers writing in Health Affairs Scholar, more than half of cancer-related deaths in the United States come from cancers that do not currently have recommended screening tests. As part of the Cancer Moonshot initiative, federal leaders have emphasized that reducing cancer deaths will require new approaches that can identify more cancers earlier.

For communities of color, the stakes are particularly high. Black Americans continue to experience higher cancer mortality rates than many other groups, while Native American, Hispanic, and rural populations often face barriers to screening and follow-up care. These inequities contribute to later diagnoses and poorer outcomes.

Dr. Gary Puckrein, president and CEO of the National Minority Quality Forum, has noted that lower-income populations, certain racial and ethnic groups, and people living in geographically isolated communities are more likely to experience advanced-stage cancer diagnoses. He argues that broader access to MCED testing could help close some of these longstanding gaps in care.

Policy Changes Aim to Expand Access

One of the biggest challenges facing MCED technology is ensuring that cost does not become another barrier. Earlier this year, Congress passed the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, a bipartisan law that creates a pathway for Medicare coverage of MCED tests once they receive approval from the U.S. Food and Drug Administration. The legislation allows the Centers for Medicare & Medicaid Services to evaluate and potentially cover these tests for eligible beneficiaries.

Advocates say the law could have an especially important impact in rural communities and underserved regions. According to the American Cancer Society Cancer Action Network, approximately 20 percent of Medicare beneficiaries live in rural areas where access to healthcare resources is often limited. Earlier detection could help patients begin treatment before cancer advances, reducing both human and financial costs.

Still, coverage alone will not solve every problem. Many patients face transportation challenges, difficulty scheduling appointments, limited access to specialists, and concerns about healthcare costs. Public health experts say community-based outreach, mobile screening programs, and culturally responsive education will remain essential to increasing participation in cancer screening efforts.

Researchers are also urging policymakers to build equity into MCED implementation from the beginning. A recent Health Affairs Scholar analysis warned that new medical technologies often reach wealthier populations first, which can unintentionally widen health disparities. The authors argued that healthcare systems, researchers, insurers, and government agencies should prioritize equitable access now rather than waiting until gaps emerge.

Questions also remain about how MCED tests will be integrated into routine care. Experts stress that blood-based screening should complement, not replace, existing guideline-recommended screenings. Patients who receive abnormal results will still need timely follow-up testing and coordinated care to confirm a diagnosis and begin treatment.

The promise of MCED testing is clear. A simple blood draw could help detect cancers earlier, including many that currently have no standard screening method. But technology alone cannot eliminate disparities that have developed over decades. Achieving that goal will require sustained investment, community engagement, strong healthcare infrastructure, and policies that ensure every patient can benefit from scientific progress. If those pieces come together, multicancer early detection could become more than a medical breakthrough. It could be an important step toward a future where the chance of surviving cancer is not determined by race, income, or ZIP code.